Symbols / BNTX
BNTX Chart
About
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 25.64B |
| Enterprise Value | 10.28B | Income | -571.60M | Sales | 3.15B |
| Book/sh | 88.54 | Cash/sh | 60.42 | Dividend Yield | — |
| Payout | 0.00% | Employees | 6772 | IPO | — |
| P/E | — | Forward P/E | -39.75 | PEG | — |
| P/S | 8.13 | P/B | 1.15 | P/C | — |
| EV/EBITDA | -21.98 | EV/Sales | 3.26 | Quick Ratio | 6.89 |
| Current Ratio | 7.12 | Debt/Eq | 1.33 | LT Debt/Eq | — |
| EPS (ttm) | -2.78 | EPS next Y | -2.57 | EPS Growth | — |
| Revenue Growth | 22.00% | Earnings | 2026-03-10 | ROA | -2.30% |
| ROE | -3.04% | ROIC | — | Gross Margin | 82.49% |
| Oper. Margin | -2.17% | Profit Margin | -18.13% | Shs Outstand | 250.93M |
| Shs Float | 99.99M | Short Float | 4.59% | Short Ratio | 4.86 |
| Short Interest | — | 52W High | 124.00 | 52W Low | 81.20 |
| Beta | 1.53 | Avg Volume | 940.03K | Volume | 1.03M |
| Target Price | $137.72 | Recom | Buy | Prev Close | $101.50 |
| Price | $102.16 | Change | 0.65% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$137.72
Mean price target
2. Current target
$102.16
Latest analyst target
3. DCF / Fair value
$-46.20
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$102.16
Low
$101.43
High
$173.23
Mean
$137.72
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-16 | up | Goldman Sachs | Neutral → Buy | $142 |
| 2025-11-10 | main | HC Wainwright & Co. | Buy → Buy | $140 |
| 2025-11-06 | main | UBS | Neutral → Neutral | $117 |
| 2025-10-23 | main | JP Morgan | Neutral → Neutral | $120 |
| 2025-10-10 | main | Morgan Stanley | Overweight → Overweight | $131 |
| 2025-09-22 | main | JP Morgan | Neutral → Neutral | $121 |
| 2025-09-08 | reit | HC Wainwright & Co. | Buy → Buy | $136 |
| 2025-08-14 | main | HC Wainwright & Co. | Buy → Buy | $136 |
| 2025-08-05 | main | Wells Fargo | Overweight → Overweight | $150 |
| 2025-08-05 | main | B of A Securities | Buy → Buy | $134 |
| 2025-07-16 | main | B of A Securities | Buy → Buy | $126 |
| 2025-07-10 | main | Morgan Stanley | Overweight → Overweight | $133 |
| 2025-06-25 | reit | HC Wainwright & Co. | Buy → Buy | $138 |
| 2025-06-16 | main | HC Wainwright & Co. | Buy → Buy | $138 |
| 2025-06-05 | main | HC Wainwright & Co. | Buy → Buy | $145 |
| 2025-06-03 | reit | Truist Securities | Buy → Buy | $155 |
| 2025-05-29 | init | Goldman Sachs | — → Neutral | $110 |
| 2025-05-22 | main | JP Morgan | Neutral → Neutral | $116 |
| 2025-05-22 | reit | HC Wainwright & Co. | Buy → Buy | $134 |
| 2025-05-14 | main | HC Wainwright & Co. | Buy → Buy | $134 |
- A Preview Of BioNTech's Earnings - Benzinga Mon, 09 Mar 2026 14
- Is BioNTech SE (BNTX) A Good Stock To Buy Now? - Finviz hu, 05 Mar 2026 18
- Is BioNTech’s (BNTX) Oncology Pivot Rewriting Its Post‑COVID Investment Story? - simplywall.st Sat, 07 Mar 2026 12
- BioNTech stock forecast: mRNA patent dispute & Q4 results - Capital.com Fri, 27 Feb 2026 08
- BioNTech earnings loom with revenue dive, pipeline progress in focus - Investing.com Mon, 09 Mar 2026 13
- Is BioNTech (BNTX) Offering Value After Recent Share Price Weakness? - Sahm Wed, 04 Mar 2026 08
- Assessing BioNTech (NasdaqGS:BNTX) Valuation After Recent Share Price Momentum Shift - Yahoo Finance ue, 24 Feb 2026 08
- Why BioNTech Stock Crushed the Market Today - The Motley Fool Fri, 05 Sep 2025 07
- BioNTech: The Market Is Pricing Low Oncology Success (NASDAQ:BNTX) - Seeking Alpha Wed, 25 Feb 2026 08
- Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too? - Barchart.com Wed, 19 Nov 2025 08
- Two early mRNA firms join forces as BioNTech buys CureVac - Stock Titan hu, 18 Dec 2025 08
- BioNTech Surges 9% On Promising Test Results For Its Cancer Smart Bomb - Investor's Business Daily Fri, 05 Sep 2025 07
- Is BioNTech (BNTX) Offering Value After Recent Share Price Weakness? - simplywall.st Wed, 04 Mar 2026 09
- BioNtech Stock Forecast 2026–2030 | Future Outlook - Capital.com ue, 17 Feb 2026 08
- Why BioNTech Stock Sank by More Than 7% Today - The Motley Fool Fri, 12 Sep 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -1.25M | 62.60M | 182.02M | 46.33M |
| TaxRateForCalcs | 0.02 | 0.22 | 0.27 | 0.32 |
| NormalizedEBITDA | -297.70M | 1.09B | 12.43B | 14.86B |
| TotalUnusualItems | -69.40M | 289.80M | 669.20M | 146.60M |
| TotalUnusualItemsExcludingGoodwill | -69.40M | 289.80M | 669.20M | 146.60M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -665.30M | 930.30M | 9.43B | 10.29B |
| ReconciledDepreciation | 298.00M | 183.40M | 123.30M | 75.20M |
| ReconciledCostOfRevenue | 541.30M | 599.80M | 3.00B | 2.91B |
| EBITDA | -367.10M | 1.38B | 13.10B | 15.00B |
| EBIT | -665.10M | 1.19B | 12.97B | 14.93B |
| NetInterestIncome | -12.60M | -7.90M | -18.90M | -27.30M |
| InterestExpense | 12.60M | 7.90M | 18.90M | 5.40M |
| InterestIncome | 437.60M | 357.60M | 48.50M | 1.50M |
| NormalizedIncome | -597.15M | 703.10M | 8.95B | 10.19B |
| NetIncomeFromContinuingAndDiscontinuedOperation | -665.30M | 930.30M | 9.43B | 10.29B |
| TotalExpenses | 3.35B | 2.91B | 5.01B | 4.05B |
| TotalOperatingIncomeAsReported | -1.31B | 690.40M | 12.64B | 15.28B |
| DilutedAverageShares | 240.18M | 242.70M | 249.79M | 259.70M |
| BasicAverageShares | 240.18M | 240.60M | 243.28M | 244.00M |
| DilutedEPS | -2.77 | 3.83 | 37.77 | 39.63 |
| BasicEPS | -2.77 | 3.87 | 38.78 | 42.18 |
| DilutedNIAvailtoComStockholders | -665.30M | 930.30M | 9.43B | 10.29B |
| NetIncomeCommonStockholders | -665.30M | 930.30M | 9.43B | 10.29B |
| NetIncome | -665.30M | 930.30M | 9.43B | 10.29B |
| MinorityInterests | 0.00 | |||
| NetIncomeIncludingNoncontrollingInterests | -665.30M | 930.30M | 9.43B | 10.29B |
| NetIncomeContinuousOperations | -665.30M | 930.30M | 9.43B | 10.29B |
| TaxProvision | -12.40M | 255.80M | 3.52B | 4.75B |
| PretaxIncome | -677.70M | 1.19B | 12.95B | 15.05B |
| OtherIncomeExpense | -69.40M | 289.80M | 669.20M | 146.60M |
| SpecialIncomeCharges | -771.10M | -29.40M | -3.00M | -9.00M |
| OtherSpecialCharges | 771.10M | 29.40M | 3.00M | 9.00M |
| RestructuringAndMergernAcquisition | -2.20M | |||
| GainOnSaleOfSecurity | 701.70M | 319.20M | 672.20M | 155.60M |
| NetNonOperatingInterestIncomeExpense | -12.60M | -7.90M | -18.90M | -27.30M |
| TotalOtherFinanceCost | 7.90M | 2.70M | 27.30M | |
| InterestExpenseNonOperating | 12.60M | 7.90M | 18.90M | 5.40M |
| InterestIncomeNonOperating | 437.60M | 357.60M | 48.50M | 1.50M |
| OperatingIncome | -595.70M | 904.20M | 12.30B | 14.93B |
| OperatingExpense | 2.81B | 2.31B | 2.01B | 1.14B |
| OtherOperatingExpenses | -47.70M | -25.80M | -66.40M | -138.30M |
| DepreciationAmortizationDepletionIncomeStatement | 7.30M | |||
| DepreciationAndAmortizationInIncomeStatement | 7.30M | |||
| ResearchAndDevelopment | 2.25B | 1.78B | 1.54B | 949.20M |
| SellingGeneralAndAdministration | 599.00M | 557.70M | 541.20M | 327.20M |
| SellingAndMarketingExpense | 67.90M | 62.70M | 59.50M | 50.40M |
| GeneralAndAdministrativeExpense | 531.10M | 495.00M | 481.70M | 276.80M |
| OtherGandA | 531.10M | 495.00M | 481.70M | 276.80M |
| InsuranceAndClaims | 21.30M | 30.40M | ||
| SalariesAndWages | 153.70M | 90.50M | ||
| GrossProfit | 2.21B | 3.22B | 14.32B | 16.07B |
| CostOfRevenue | 541.30M | 599.80M | 3.00B | 2.91B |
| TotalRevenue | 2.75B | 3.82B | 17.31B | 18.98B |
| OperatingRevenue | 2.43B | 3.78B | 17.15B | 18.98B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 8.58M | 10.83M | 5.34M | 3.79M |
| OrdinarySharesNumber | 239.97M | 237.73M | 243.22M | 242.52M |
| ShareIssued | 248.55M | 248.55M | 248.55M | 246.31M |
| TotalDebt | 254.20M | 219.10M | 212.20M | 301.50M |
| TangibleBookValue | 18.24B | 19.08B | 19.84B | 11.69B |
| InvestedCapital | 19.67B | 20.46B | 20.27B | 12.20B |
| WorkingCapital | 16.28B | 17.46B | 18.97B | 11.59B |
| NetTangibleAssets | 18.24B | 19.08B | 19.84B | 11.69B |
| CommonStockEquity | 19.41B | 20.25B | 20.06B | 11.89B |
| TotalCapitalization | 19.63B | 20.44B | 20.23B | 12.07B |
| TotalEquityGrossMinorityInterest | 19.41B | 20.25B | 20.06B | 11.89B |
| StockholdersEquity | 19.41B | 20.25B | 20.06B | 11.89B |
| GainsLossesNotAffectingRetainedEarnings | -1.33B | -984.60M | -848.90M | 93.90M |
| OtherEquityAdjustments | -1.33B | -984.60M | -848.90M | 93.90M |
| TreasuryStock | 8.60M | 10.80M | 5.30M | 3.80M |
| RetainedEarnings | 19.10B | 19.76B | 18.83B | 9.88B |
| AdditionalPaidInCapital | 1.40B | 1.23B | 1.83B | 1.67B |
| CapitalStock | 248.60M | 248.60M | 248.60M | 246.30M |
| CommonStock | 248.60M | 248.60M | 248.60M | 246.30M |
| TotalLiabilitiesNetMinorityInterest | 3.12B | 2.76B | 3.22B | 3.94B |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 595.40M | 689.90M | 272.90M | 455.50M |
| OtherNonCurrentLiabilities | 134.40M | 51.90M | 23.10M | 18.90M |
| TradeandOtherPayablesNonCurrent | 0.00 | 10.40M | 4.40M | |
| NonCurrentDeferredLiabilities | 225.40M | 438.20M | 54.60M | 75.70M |
| NonCurrentDeferredRevenue | 183.00M | 398.50M | 48.40M | 9.00M |
| NonCurrentDeferredTaxesLiabilities | 42.40M | 39.70M | 6.20M | 66.70M |
| LongTermDebtAndCapitalLeaseObligation | 214.70M | 191.00M | 176.20M | 171.60M |
| LongTermDebt | 214.70M | 191.00M | 176.20M | 171.60M |
| LongTermProvisions | 20.90M | 8.80M | 8.60M | 184.90M |
| CurrentLiabilities | 2.52B | 2.07B | 2.95B | 3.48B |
| OtherCurrentLiabilities | 1.61B | 540.30M | 1.65B | 1.24B |
| CurrentDeferredLiabilities | 294.90M | 353.30M | 77.10M | 186.10M |
| CurrentDeferredRevenue | 294.90M | 353.30M | 77.10M | 186.10M |
| CurrentDebtAndCapitalLeaseObligation | 39.50M | 28.10M | 36.00M | 129.90M |
| CurrentDebt | 39.50M | 28.10M | 36.00M | 129.90M |
| OtherCurrentBorrowings | 39.50M | 28.10M | 36.00M | 129.90M |
| CurrentProvisions | 144.80M | 269.30M | 391.60M | 200.20M |
| PayablesAndAccruedExpenses | 431.20M | 879.50M | 800.00M | 1.73B |
| Payables | 431.20M | 879.50M | 800.00M | 1.73B |
| TotalTaxPayable | 4.50M | 525.50M | 595.90M | 1.57B |
| IncomeTaxPayable | 4.50M | 525.50M | 595.90M | 1.57B |
| AccountsPayable | 426.70M | 354.00M | 204.10M | 160.00M |
| TotalAssets | 22.53B | 23.01B | 23.28B | 15.83B |
| TotalNonCurrentAssets | 3.73B | 3.48B | 1.36B | 758.50M |
| OtherNonCurrentAssets | 26.30M | 83.40M | 6.50M | 14.40M |
| NonCurrentDeferredAssets | 81.70M | 81.30M | 229.60M | 0.00 |
| NonCurrentDeferredTaxesAssets | 81.70M | 81.30M | 229.60M | 0.00 |
| NonCurrentAccountsReceivable | 9.80M | |||
| InvestmentsAndAdvances | 1.25B | 1.18B | 80.20M | 21.30M |
| InvestmentinFinancialAssets | 1.25B | 1.18B | 80.20M | 21.30M |
| AvailableForSaleSecurities | 1.25B | 1.18B | 80.20M | 21.30M |
| GoodwillAndOtherIntangibleAssets | 1.17B | 1.17B | 219.70M | 202.40M |
| OtherIntangibleAssets | 790.40M | 804.10M | 158.50M | 144.60M |
| Goodwill | 380.60M | 362.50M | 61.20M | 57.80M |
| NetPPE | 1.18B | 971.60M | 821.10M | 520.40M |
| AccumulatedDepreciation | -322.40M | -211.80M | -116.30M | -74.20M |
| GrossPPE | 1.51B | 1.18B | 937.40M | 594.60M |
| ConstructionInProgress | 460.60M | 389.50M | 235.50M | 94.30M |
| OtherProperties | 437.60M | 348.70M | 278.40M | 221.20M |
| MachineryFurnitureEquipment | 100.00K | |||
| BuildingsAndImprovements | 238.20M | 209.80M | 206.50M | 175.00M |
| LandAndImprovements | 369.40M | 235.40M | 217.00M | 104.10M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 18.80B | 19.53B | 21.92B | 15.07B |
| OtherCurrentAssets | 212.70M | 280.90M | 271.90M | 113.40M |
| CurrentDeferredAssets | 48.50M | |||
| Inventory | 283.30M | 357.70M | 439.60M | 502.50M |
| FinishedGoods | 7.90M | 6.20M | 8.90M | 169.70M |
| WorkInProcess | 7.30M | 4.00M | 21.00M | 84.50M |
| RawMaterials | 268.10M | 347.50M | 409.70M | 248.30M |
| Receivables | 1.52B | 2.34B | 7.15B | 12.38B |
| OtherReceivables | 10.00M | 4.90M | ||
| TaxesReceivable | 50.00M | 179.10M | 400.00K | 400.00K |
| AccountsReceivable | 1.46B | 2.16B | 7.15B | 12.38B |
| CashCashEquivalentsAndShortTermInvestments | 16.78B | 16.55B | 14.06B | 2.07B |
| OtherShortTermInvestments | 7.02B | 4.89B | 189.40M | 381.60M |
| CashAndCashEquivalents | 9.76B | 11.66B | 13.88B | 1.69B |
| CashEquivalents | 9.31B | 11.21B | 12.55B | 600.00M |
| CashFinancial | 450.00M | 453.10M | 1.33B | 1.09B |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -244.60M | 4.67B | 13.21B | 735.70M |
| RepurchaseOfCapitalStock | 0.00 | -738.50M | -986.40M | 0.00 |
| RepaymentOfDebt | -45.90M | -40.40M | -59.90M | -66.70M |
| IssuanceOfDebt | 0.00 | 300.00K | 800.00K | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 0.00 | 110.50M | 160.90M |
| CapitalExpenditure | -452.30M | -705.50M | -363.30M | -154.00M |
| EndCashPosition | 9.76B | 11.66B | 13.88B | 1.69B |
| OtherCashAdjustmentOutsideChangeinCash | 2.80M | 164.80M | -500.00K | 0.00 |
| BeginningCashPosition | 11.66B | 13.88B | 1.69B | 1.21B |
| EffectOfExchangeRateChanges | 14.80M | -14.50M | 60.10M | 64.70M |
| ChangesInCash | -1.92B | -2.36B | 12.12B | 417.80M |
| FinancingCashFlow | -45.90M | -778.60M | -1.42B | 94.20M |
| CashFlowFromContinuingFinancingActivities | -45.90M | -778.60M | -1.42B | 94.20M |
| CashDividendsPaid | 0.00 | 0.00 | -484.30M | 0.00 |
| NetCommonStockIssuance | 0.00 | -738.50M | -875.90M | 160.90M |
| CommonStockPayments | 0.00 | -738.50M | -986.40M | 0.00 |
| CommonStockIssuance | 0.00 | 0.00 | 110.50M | 160.90M |
| NetIssuancePaymentsOfDebt | -45.90M | -40.10M | -59.10M | -66.70M |
| NetLongTermDebtIssuance | -45.90M | -40.10M | -59.10M | -66.70M |
| LongTermDebtPayments | -45.90M | -40.40M | -59.90M | -66.70M |
| LongTermDebtIssuance | 0.00 | 300.00K | 800.00K | 0.00 |
| InvestingCashFlow | -2.08B | -6.95B | -35.30M | -566.10M |
| CashFlowFromContinuingInvestingActivities | -2.08B | -6.95B | -35.30M | -566.10M |
| NetInvestmentPurchaseAndSale | -1.63B | -5.91B | 327.40M | -394.70M |
| SaleOfInvestment | 10.74B | 1.22B | 375.20M | |
| PurchaseOfInvestment | -12.37B | -7.13B | -47.80M | -394.70M |
| NetBusinessPurchaseAndSale | 0.00 | -336.90M | 0.00 | -20.80M |
| SaleOfBusiness | 0.00 | |||
| PurchaseOfBusiness | 0.00 | -336.90M | 0.00 | -20.80M |
| NetIntangiblesPurchaseAndSale | -165.80M | -455.40M | -34.10M | -26.50M |
| PurchaseOfIntangibles | -165.80M | -455.40M | -34.10M | -26.50M |
| NetPPEPurchaseAndSale | -285.30M | -250.10M | -328.60M | -124.10M |
| SaleOfPPE | 1.20M | 600.00K | 3.40M | |
| PurchaseOfPPE | -286.50M | -250.10M | -329.20M | -127.50M |
| OperatingCashFlow | 207.70M | 5.37B | 13.58B | 889.70M |
| CashFlowFromContinuingOperatingActivities | 207.70M | 5.37B | 13.58B | 889.70M |
| TaxesRefundPaid | -389.20M | -482.90M | -4.22B | -3.46B |
| InterestReceivedCFO | 474.90M | 258.20M | 29.30M | 1.20M |
| InterestPaidCFO | -13.50M | -5.40M | -21.50M | -12.20M |
| ChangeInWorkingCapital | 1.22B | 5.57B | 4.52B | -10.73B |
| ChangeInPayablesAndAccruedExpense | 758.40M | 118.90M | 85.70M | 1.52B |
| ChangeInPayable | 758.40M | 118.90M | 85.70M | 1.52B |
| ChangeInAccountPayable | 758.40M | 118.90M | 85.70M | 1.52B |
| ChangeInInventory | 74.50M | 81.90M | 62.90M | -438.40M |
| ChangeInReceivables | 387.70M | 5.37B | 4.37B | -11.81B |
| ChangesInAccountReceivables | 4.37B | -11.81B | ||
| OtherNonCashItems | -701.10M | -1.28B | -297.90M | 199.10M |
| StockBasedCompensation | 100.90M | 51.40M | 108.60M | 93.90M |
| DepreciationAmortizationDepletion | 298.00M | 183.40M | 123.30M | 75.20M |
| DepreciationAndAmortization | 298.00M | 183.40M | 123.30M | 75.20M |
| AmortizationCashFlow | 40.50M | 22.00M | 16.80M | |
| AmortizationOfIntangibles | 40.50M | 22.00M | 16.80M | |
| Depreciation | 298.00M | 183.40M | 123.30M | 75.20M |
| OperatingGainsLosses | -105.20M | -118.70M | 385.10M | -325.60M |
| GainLossOnInvestmentSecurities | 4.60M | 175.50M | -241.00M | 57.30M |
| NetForeignCurrencyExchangeGainLoss | -109.50M | -298.00M | 625.50M | -387.50M |
| GainLossOnSaleOfPPE | -300.00K | 3.80M | 600.00K | 4.60M |
| NetIncomeFromContinuingOperations | -677.70M | 1.19B | 12.95B | 15.05B |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for BNTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|